|
|
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel
|
|
|
T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results
|
|
|
T2 Biosystems to Appear on the Benzinga All Access Show on June 17, 2022
|
|
|
T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule; Company to Transfer to Nasdaq Capital Market
|
|
|
T2 Biosystems Announces Issuance of U.S. Patent for Direct Detection of Lyme Disease
|
|
|
T2 Biosystems Announces First Quarter 2022 Financial Results
|
|
|
T2 Biosystems Announces Receipt of Nasdaq Delisting Notice
|
|
|
T2 Biosystems Announces Formation and Members of Scientific Advisory Board
|
|
|
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for T2Biothreat Panel
|
|
|
T2 Biosystems to Report First Quarter 2022 Financial Results on May 5, 2022
|
